Harvard Bioscience
(HBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-1999 | |
| Cash Flows From Operating Activities | |
| Net Income | -29,420 |
| Depreciation Amortization | 1,257 |
| Income taxes - deferred | -1,310 |
| Accounts receivable | -2,282 |
| Accounts payable and accrued liabilities | 541 |
| Other Working Capital | -612 |
| Other Operating Activity | 34,753 |
| Operating Cash Flow | $2,926 |
| Cash Flows From Investing Activities | |
| PPE Investments | -298 |
| Net Acquisitions | -8,127 |
| Other Investing Activity | -122 |
| Investing Cash Flow | $-8,546 |
| Cash Flows From Financing Activities | |
| Change In Short Term Borrowing | 2,300 |
| Debt Issued | 5,500 |
| Debt Repayment | -461 |
| Dividend Paid | -122 |
| Other Financing Activity | -225 |
| Financing Cash Flow | $6,993 |
| Exchange Rate Effect | 66 |
| Beginning Cash Position | 957 |
| End Cash Position | 2,396 |
| Net Cash Flow | $1,439 |
| Free Cash Flow | |
| Operating Cash Flow | 2,926 |
| Capital Expenditure | -333 |
| Free Cash Flow | 2,594 |